Goldman Sachs lowered the firm’s price target on Calumet (CLMT) to $21 from $22 but keeps a Buy rating on the shares ahead of its Q4 results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback